ConductScience.org, home

Paper9737679

Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product.

Kiyoi H and 6 others. Leukemia, 1998. Cited by 391 papers, by iCite.

Cite this record

ConductScience Library. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Papers, record 9737679. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/9737679

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product.
PubMed
Journal
Leukemia
PubMed
Year
1998
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
391
iCite
Relative citation ratio, by iCite
7.21
iCite
Revised in PubMed
2019-09-15
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Kiyoi HH
2Towatari MM
3Yokota SS
4Hamaguchi MM
5Ohno RR
6Saito HH
7Naoe TT

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Leukemia, MyeloidMajor topic
MutationMajor topic
Neoplasm ProteinsMajor topic
Proto-Oncogene ProteinsMajor topic
Receptor Protein-Tyrosine KinasesMajor topic
Acute Disease
Animals
COS Cells
Chromosome Mapping
Humans
Myelodysplastic Syndromes
Phosphorylation
Receptors, Platelet-Derived Growth Factor
Sequence Analysis
fms-Like Tyrosine Kinase 3

Source PubMed

Download CSV of topics

Cited by171

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 391 citations.

PMIDTitleJournalYearIn PapersSource
42619896FLT3-ITD signals for CEBPA and p53 proteolysis by the ubiquitin-proteosome pathway.Res Sq2026https://conductscience.org/library/papers/42619896PubMed
42523299FLT3-ITD signals for CEBPA and p53 proteolysis by the ubiquitin-proteosome pathway.bioRxiv2026https://conductscience.org/library/papers/42523299PubMed
42434847QuANTUM-Wild: a Phase III, randomized trial of quizartinib in newly diagnosed FLT3-ITD-negative acute myeloid leukemia.Future Oncol2026https://conductscience.org/library/papers/42434847PubMed
42200022Efficacy and safety of FLT3 inhibitors for acute myeloid leukemia: a network meta-analysis.Front Oncol2026https://conductscience.org/library/papers/42200022PubMed
42139346P300/CBP inhibition with inobrodib in combination with gilteritinib and venetoclax targets leukemia stem cells in epigenetic mutant AML.Sci Adv2026https://conductscience.org/library/papers/42139346PubMed
41896977RGX-019-MMAE inhibits leukemia progression by targeting MER proto-oncogene tyrosine kinase (MERTK) in acute myeloid leukemia.J Exp Clin Cancer Res2026https://conductscience.org/library/papers/41896977PubMed
41893037Targeted Therapy in Acute Myeloid Leukemia: Current Approaches and Novel Directions.J Pers Med2026https://conductscience.org/library/papers/41893037PubMed
41082703Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study.J Clin Oncol2026https://conductscience.org/library/papers/41082703PubMed
41052406FLT3-ITD measurable residual disease from the QuANTUM-First trial.Blood Adv2026https://conductscience.org/library/papers/41052406PubMed
38915455Clinical profile of FTL3-ITD mutation in West Algerian population with acute myeloid leukemia.Mol Biol Res Commun2024https://conductscience.org/library/papers/38915455PubMed
38495876Leukemic mutation FLT3-ITD is retained in dendritic cells and disrupts their homeostasis leading to expanded Th17 frequency.Front Immunol2024https://conductscience.org/library/papers/38495876PubMed
37686670Expanding the Clinical Utility of Targeted RNA Sequencing Panels beyond Gene Fusions to Complex, Intragenic Structural Rearrangements.Cancers (Basel)2023https://conductscience.org/library/papers/37686670PubMed
37606386Shift of N-MYC Oncogene Expression in AML Patients Carrying the FLT3-ITD Mutation.Pathophysiology2023https://conductscience.org/library/papers/37606386PubMed
36698434FMS-Like Tyrosine Kinase 3 Inhibitors in the Treatment of Acute Myeloid Leukemia: An Update on the Emerging Evidence and Safety Profile.Onco Targets Ther2023https://conductscience.org/library/papers/36698434PubMed
36681742BET inhibitors rescue anti-PD1 resistance by enhancing TCF7 accessibility in leukemia-derived terminally exhausted CD8+ T cells.Leukemia2023https://conductscience.org/library/papers/36681742PubMed
36567628ACC010, a novel BRD4 inhibitor, synergized with homoharringtonine in acute myeloid leukemia with FLT3-ITD.Mol Oncol2023https://conductscience.org/library/papers/36567628PubMed
36532642Evaluation of FLT3-ITD Mutations and MDR1 Gene Expression in AML Patients.Iran J Pathol2022https://conductscience.org/library/papers/36532642PubMed
36450475Successful Pre- and Post-transplant Administration of Gilteritinib in a Patient with Relapsed and Refractory Acute Myeloid Leukemia Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation.Intern Med2023https://conductscience.org/library/papers/36450475PubMed
36293564Clinical Efficacies of FLT3 Inhibitors in Patients with Acute Myeloid Leukemia.Int J Mol Sci2022https://conductscience.org/library/papers/36293564PubMed
36289703Recent Advances in the Development of Anti-FLT3 CAR T-Cell Therapies for Treatment of AML.Biomedicines2022https://conductscience.org/library/papers/36289703PubMed

See all 171 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
FLT32322Swiss-Prot's referenceshttps://conductscience.org/library/genes/2322

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/9737679

GET https://conductscience.org/api/papers/v1/9737679/cited_by?page=2